Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue							31.13M -	29.94M 3.82%	49.11M 64.00%	41.59M 15.32%	43.95M 5.68%
cost of revenue										11.98M -
gross profit							31.13M -	29.94M 3.82%	49.11M 64.00%	29.60M 39.72%	43.95M 48.45%
selling and marketing expenses											-2.54M -
general and administrative expenses							34.11M -	35.78M 4.90%	40.90M 14.30%	52.20M 27.64%	59.84M 14.63%
selling general and administrative expenses							34.11M -	35.78M 4.90%	40.90M 14.30%	52.20M 27.64%	57.30M 9.76%
research and development expenses							55.68M -	70.04M 25.79%	98.19M 40.19%	149.42M 52.18%	140.66M 5.87%
other expenses			7.91M -	6.05M 23.49%	9.84M 62.54%	8.12M 17.50%	196K 97.59%		-1.14M -	1.06M 193.30%
cost and expenses							89.79M -	105.82M 17.85%	139.08M 31.43%	201.62M 44.97%	200.49M 0.56%
operating expenses	3.79M -	3.52M 7.19%	26.63M 656.35%	31.96M 20.04%	67.21M 110.28%	80.41M 19.64%	89.79M 11.66%	105.82M 17.85%	139.08M 31.43%	201.62M 44.97%	197.95M 1.82%
interest expense									-129K -	2.72M 2,210.08%	14.51M 433.06%
ebitda							-60.27M -	-65.00M 7.85%	-113.15M 74.08%	-184.78M 63.30%	-154.01M 16.65%
operating income							-58.66M -	-75.88M 29.36%	-89.98M 18.58%	-160.04M 77.87%	-156.55M 2.18%
depreciation and amortization							-1.61M -	10.88M 773.44%	-23.18M 313.11%	-24.74M 6.73%	2.54M 110.27%
total other income expenses net							3.70M -	-9.13M 346.81%	23.40M 356.23%	29.80M 27.37%	4.80M 83.89%
income before tax							-54.96M -	-85.01M 54.68%	-66.58M 21.68%	-130.24M 95.62%	-151.75M 16.52%
income tax expense							194K -	503K 159.28%	239K 52.49%	959K 301.26%	3.19M 232.85%
net income	-13.68M -	-21.17M 54.73%	-25.35M 19.73%	-49.67M 95.96%	-87.69M 76.54%	-27.76M 68.34%	-55.15M 98.66%	-85.51M 55.05%	-66.82M 21.86%	-131.19M 96.35%	-154.94M 18.10%
weighted average shs out	15.41M -	15.41M 0%	15.41M 0%	13.23M 14.14%	19.20M 45.11%	22.29M 16.10%	24.22M 8.67%	29.26M 20.80%	38.64M 32.07%	44.92M 16.25%	51.61M 14.89%
weighted average shs out dil	15.41M -	15.41M 0%	15.41M 0%	13.23M 14.14%	19.20M 45.11%	22.29M 16.10%	24.22M 8.67%	29.26M 20.80%	38.64M 32.07%	44.92M 16.25%	51.61M 14.89%
eps	-0.89 -	-1.37 53.93%	-1.65 20.44%	-3.75 127.27%	-4.57 21.87%	-1.25 72.65%	-2.28 82.40%	-2.92 28.07%	-1.73 40.75%	-2.92 68.79%	-3 2.74%
epsdiluted	-0.89 -	-1.37 53.93%	-1.65 20.44%	-3.75 127.27%	-4.57 21.87%	-1.25 72.65%	-2.28 82.40%	-2.92 28.07%	-1.73 40.75%	-2.92 68.79%	-3 2.74%

NL:MERUS

Merus N.V.

Last Close

44.35

22/11 21:00

Market Cap

3.70B

Beta: -

Volume Today

606.90K

Avg: -

Preview